Ozanimod
- Generic Name
- Ozanimod
- Brand Names
- Zeposia, Zeposia 7-day Starter Pack, Zeposia Starter Kit
- Drug Type
- Small Molecule
- Chemical Formula
- C23H24N4O3
- CAS Number
- 1306760-87-1
- Unique Ingredient Identifier
- Z80293URPV
- Background
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020. The US approval was followed by the approval in Canada on October 2, 2020. In November 202...
- Indication
Ozanimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is also used to treat moderately to severely active ulcerative colitis (UC) in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Moderately to Severely Active Ulcerative Colitis, Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 606
- Registration Number
- NCT03440385
- Locations
- 🇫🇮
Local Institution - 614, Turku, Finland
🇺🇸Local Institution - 202, Scottsdale, Arizona, United States
🇺🇸Ucsd Medical Center, La Jolla, California, United States
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 625
- Registration Number
- NCT03440372
- Locations
- 🇲🇽
Local Institution - 525, Monterrey, Nuevo León, Mexico
🇮🇳Local Institution - 443, Jaipur, Rajasthan, India
🇲🇽Local Institution - 532, Monterrey, Nuevo León, Mexico
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1346
- Registration Number
- NCT02294058
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Neurological Research Institute Inc, Columbus, Ohio, United States
🇺🇸The Polyclinic, Seattle, Washington, United States
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1320
- Registration Number
- NCT02047734
- Locations
- 🇺🇸
Neurostudies Inc, Port Charlotte, Florida, United States
🇵🇱RESMEDICA Spolka z o.o., Kielce, Poland
🇵🇱Receptos Study Site 402, Olsztyn, Poland
Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 199
- Registration Number
- NCT01647516
- Locations
- 🇸🇰
Slovak Research Center, Ilava, Slovakia
🇧🇬University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria
🇧🇬University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 258
- Registration Number
- NCT01628393
- Locations
- 🇧🇪
Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, Belgium
🇧🇪Clinique Saint-Pierre, Ottignies, Belgium
🇧🇪Cliniques Universitaires St-Luc, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.